Arvinas Inc. Common Stock (ARVN)

About ARVN

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

246

Website

www.arvinas.com/

Fundamentals

1-day range

$9.03$9.24

Market cap

$567.55M

P/E (trailing)

62.96

P/E (forward)

-2.99

EPS (trailing)

$0.16

Dividend yield

—

Beta

1.79

Avg. volume

788.0K

Forecasts

14 analyst ratings

Arvinas Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ARVN

  Arvinas Inc. Common Stock

  $9.16

  ▼ 0.87%
  Market cap $567.55MP/E 62.96
  $6.97$14.51
• CRMD

  CorMedix Inc. Common Stock

  $8.31

  ▼ 0.06%
  Market cap $589.17MP/E 3.53
  $6.13$14.96
• SGMT

  Sagimet Biosciences Inc. Series A Common Stock

  $10.55

  ▼ 1.86%
  Market cap $539.71MP/E —
  $4.5$11.15
• MPLT

  MapLight Therapeutics Inc. Common Stock

  $12.64

  ▲ 0.80%
  Market cap $602.19MP/E —
  $9.1$40.43
• CBIO

  Crescent Biopharma Inc. Common Stock

  $17.74

  ▼ 0.14%
  Market cap $610.27MP/E —
  $8.72$27.41
• OVID

  Ovid Therapeutics Inc. Common Stock

  $2.81

  ▼ 4.10%
  Market cap $494.60MP/E —
• AQST

  Aquestive Therapeutics Inc. Common Stock

  $5.02

  ▼ 2.71%
  Market cap $491.83MP/E —

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
  SeekingAlpha · 8/28/2026
• Arvinas (ARVN) Q2 2026 Earnings Call Transcript
  Yahoo · 8/11/2026
• Evercore ISI Group Maintains Outperform on Arvinas, Lowers Price Target to $14
  benzinga · 8/10/2026
• Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
  Yahoo · 8/10/2026
• Evercore ISI Group Maintains Outperform on Arvinas, Lowers Price Target to $14
  Benzinga · 8/10/2026
• Citigroup Maintains Buy on Arvinas, Lowers Price Target to $21
  Benzinga · 8/10/2026
• Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
  Yahoo · 8/6/2026
• Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead
  SeekingAlpha · 8/5/2026
• Wells Fargo Downgrades Arvinas to Equal-Weight, Lowers Price Target to $11
  Benzinga · 8/5/2026

• Kennedy Edward Moore Jr. · June 24, 2026 · Grant

  22.7K
• Kennedy Edward Moore Jr. · June 24, 2026 · Grant

  15.5K
• Morrison Briggs · June 24, 2026 · Grant

  22.7K
• Morrison Briggs · June 24, 2026 · Grant

  15.5K
• Smaldone Alsup Laurie · June 24, 2026 · Grant

  22.7K
• Smaldone Alsup Laurie · June 24, 2026 · Grant

  15.5K
• Bain Linda · June 24, 2026 · Grant

  22.7K
• Bain Linda · June 24, 2026 · Grant

  15.5K
• Cunningham Everett · June 24, 2026 · Grant

  22.7K
• Cunningham Everett · June 24, 2026 · Grant

  15.5K
• Leslie Norwalk V · June 24, 2026 · Grant

  22.7K
• Leslie Norwalk V · June 24, 2026 · Grant

  15.5K
• Saik Andrew · June 24, 2026 · Sale

  5.7K @ $8.16
• Cacace Angela M · June 17, 2026 · Sale

  2.6K @ $7.6
• Teel Randy · May 21, 2026 · Sale

  2.2K @ $9.04

Institutional Ownership

March 31, 2026

Total shares held

49.57M

Total value held

$502.06M

Institutional holders

199